An experimental model on the protective impact of nanosilymarin on ulcerative colitis induced by TNBS in rats: The inclusion of TLR4 / NF-κB pathway

Document Type : Research Paper


1 Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

3 Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran


Objective(s): The present work aimed to assess the protective impacts of nanosilymarin or silymarin on colitis induced by TNBS in rats. 
Materials and Methods: Induction of acute colitis was conducted by rectally administering 2 ml of TNBS solution. About 2 hr followed by induction of colitis, the rates were given dexamethasone (2 mg / kg), normal saline, silymarin (50, 100, and 200 mg / kg), and nanosilymarin (50,100, and 200 mg / kg) orally for two weeks. Damage was assessed at the macroscopic and microscopic levels. MPO enzyme activity was measured using biochemical technique and also ELISA kit was used to measure tissue levels of TNF-α and IL-1β and Western blot analysis was utilized to study the expression level of P65 TLR4 and pNF-κB proteins. According to the results, dexamethasone (2 mg / kg) and nanosilimarin (200 mg / kg) reduced tissue damages than the TNBS group (P<0.001). Moreover, these drugs reduced MPO activity (P<0.001) and levels of TNF-α and IL-1β (P<0.001) in colon tissue than the TNBS group and also the expression of p65 TLR4 and pNF-κB proteins was decreased when in comparison to the TNBS group.
Conclusion: It is proposed that nanosilimarin reduce colon inflammation in TNBS-induced experimental colitis by inhibition of the TLR4 / NFκB molecular path.


1.    Sinopoulou V, Gordon M, Dovey TM, Akobeng AK. Interventions for the management of abdominal pain in ulcerative colitis. Cochrane Database Sys Rev. 2021(7).
2.    Rashidian A, Dejban P, Karami Fard K, Abdollahi A, Chamanara M, Dehpour A, et al. Bupropion Ameliorates Acetic Acid–Induced Colitis in Rat: the Involvement of the TLR4/NF-kB Signaling Pathway. Inflammation. 2020;43(5):1999-2009.
3.    Goyal N, Rana A, Ahlawat A, Bijjem KR, Kumar P. Animal models of inflammatory bowel disease: a review. Inflammopharmacology. 2014;22(4):219-233.
4.    Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406(6797):782-787.
5.    Dejban P, Nikravangolsefid N, Chamanara M, Dehpour A, Rashidian A. The role of medicinal products in the treatment of inflammatory bowel diseases (IBD) through inhibition of TLR4/NF‐kappaB pathway. Phytotherapy Research. 2021;35(2):835-845.
6.    Rashidian A, Muhammadnejad A, Dehpour A-R, Mehr SE, Akhavan MM, Shirkoohi R, et al. Atorvastatin attenuates TNBS-induced rat colitis: the involvement of the TLR4/NF-kB signaling pathway. Inflammopharmacology. 2016;24(2):109-118.
7.    Aderem A. Role of Toll-like receptors in inflammatory response in macrophages. Critical care medicine. 2001;29(7):S16-S18.
8.    Jafari RM, Shayesteh S, Ala M, Yousefi-Manesh H, Rashidian A, Hashemian SM, et al. Dapsone ameliorates colitis through TLR4/NF-kB pathway in TNBS induced colitis model in rat. Archives of medical research. 2021;52(6):595-602.
9.    Lovelace ES, Wagoner J, MacDonald J, Bammler T, Bruckner J, Brownell J, et al. Silymarin suppresses cellular inflammation by inducing reparative stress signaling. Journal of natural products. 2015;78(8):1990-2000.
10.    Mombeini M, Saki G, Khorsandi L, Bavarsad N. Effects of silymarin-loaded nanoparticles on HT-29 human colon cancer cells. Medicina. 2018;54(1):1-9.
11.    Javed S, Kohli K, Ali M. Reassessing bioavailability of silymarin. Alternative medicine review. 2011;16(3):239.
12.    Sohrabi MJ, Dehpour A-R, Attar F, Hasan A, Mohammad-Sadeghi N, Meratan AA, et al. Silymarin-albumin nanoplex: preparation and its potential application as an antioxidant in nervous system in vitro and in vivo. International journal of pharmaceutics. 2019;572:118824.
13.    Rashidian A, Roohi P, Mehrzadi S, Ghannadi AR, Minaiyan M. Protective effect of Ocimum basilicum essential oil against acetic acid–induced colitis in rats. Journal of evidence-based complementary & alternative medicine. 2016;21(4):NP36-NP42.
14.    Bou-Fersen AM, Anim JT, Khan I. Experimental colitis is associated with ultrastructural changes in inflamed and uninflamed regions of the gastrointestinal tract. Medical Principles and Practice. 2008;17(3):190-196.
15.    Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54. e42.
16.    Dou W, Zhang J, Sun A, Zhang E, Ding L, Mukherjee S, et al. Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling. British journal of nutrition. 2013;110(4):599-608.
17.    Scheiffele F, Fuss IJ. Induction of TNBS colitis in mice. Curr Protoc Immunol. 2002;49(1):Chapter 15:Unit 15.19.
18.    Atreya I, Atreya R, Neurath M. NF‐κB in inflammatory bowel disease. Journal of internal medicine. 2008;263(6):591-596.
19.    Colitis-Pathophysiology U. Inflammatory bowel disease part I: ulcerative colitis-pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2003;8(3):247-283.
20.    Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants. 2015;4(1):204-247.
21.    Fallah M, Davoodvandi A, Nikmanzar S, Aghili S, Mirazimi SMA, Aschner M, et al. Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer. Biomedicine & Pharmacotherapy. 2021;142:112024.
22.    Mohsin RH, Al-Zamely HA. Treatment of induced diabetes in rats by nanosilymarin. Plant Archives. 2021;21(1):1654-1657.